Vasgen Ltd is a new biotech enterprise that aims to develop unique, antibody-based therapeutic and investigative technologies that will address important clinical needs in the cancer and ophthalmology space. Vasgen Ltd has developed a novel technology platform which will allow the targeting of different members of the metzincin gene super family, which are known to play an important role in many diseases.